Assessment Of Soluble Fas Ligand In Patients With Chronic Myeloid Leukemia
DOI:
https://doi.org/10.46966/msjar.v3i4.79Keywords:
Chronic Myeloid Leukemia, CML, Soluble Fas Ligand, Sfasl, Philadelphia Chromosome, Ph Chromosome.Abstract
Background: Soluble FasL (sFasL) generating from Membrane-bound FasL (mFasL) cleaved by matrix metalloproteinases (MMPs). sFasL inhibits the apoptotic and inflammatory activity of mFasL because of sFasL competes with the mFasL and binds to Fas. To evaluate serum soluble Fas ligand (sFasL) level in patients with chronic myeloid leukemia.
Materials and Method: Serum levels of sFasL were measured by ELISA method after venous blood was collected from 56 CML patients (newly diagnosed and optimally treated) and 28 healthy subjects as control group.
Results: There were no significant increases in serum sFasL patient compared to healthy control with P=0.07. When the mean sFasL concentration was obviously highest in newly diagnosed (216.9pg/ml) followed by healthy control (152.5pg/ml) and lowest in optimally treated (147.7 pg/ml).
Conclusion: Production of sFasL in tumor patients may be a key mechanism to inhibit Fas-mediated apoptosis.
References
Shallis RM.; Wang R.; Davidoff A.; Ma X.; Podoltsev NA. & Zeidan AM. (2020). Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map. Blood Rev., 42:100706. doi:10.1016/j.blre.2020.100706
Nannya Y.; Imai Y.; Hangaishi A. & Kurokawa M. (2008). An Extended Mathematical Model of Pathophysiology and Response to Treatment in Chronic Myelogenous Leukemia. Blood,112 (11): 4220.
How J.; Venkataraman V.& Hobbs G.S. (2021).Blast and accelerated phase CML: room for improvement. Hematology Am Soc Hematol Educ Program, 2021(1): 122–128. doi: https://doi.org/10.1182/hematology.2021000240
Kang ZJ.; Liu YF.; Xu LZ.; Long ZJ.; Huang D.; Yang Y.; Liu B.; Feng JX.; Pan YJ.; Yan JS. & Liu Q.(2016). The Philadelphia chromosome in leukemogenesis. Chinese Journal of Cancer, 35:48.
DOI: 10.1186/s40880-016-0108-0
Granatowicz A.; Piatek CI.; Moschiano E.; El-Hemaidi I.; Armitage JD. & Akhtari M. (2015). An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians. Korean Journal of Family Medicine, 36(5): 197– 202. doi: 10.4082/kjfm.2015.36.5.197.
De la Fuente J.; Baruchel A.; Biondi A.; de Bont E.; Dresse MF.; Suttorp M. & Millot F. (2014). Chronic Myeloid Leukaemia Committee. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. British Journal of Haematology, 167(1):3347.doi:10.1111/bjh.12977.
Liu W.; Ramagopal U.; Cheng H.; Bonanno JB.; Toro R.; Bhosle R.; Zhan C.; Almo SC. (2016). Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3. Structure, 24 (11): 2016-2023. DOI: https://doi.org/10.1016/j.str.2016.09.009.
Kim WU.; Kwok SK.; Hong KH.; Yoo SA.; Kong JS.; Choe J. & Cho CS. (2007). Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis. Arthritis Research &Therapy, 9(2): R42.
Dockrell D.H. (2003). The multiple roles of Fas ligand in the pathogenesis of infectious diseases. Clinical Microbiology and Infection, 9(8): 766-779. https://doi.org/10.1046/j.1469-0691.2003.00669.x.
Jeong D.; Kim HS.; Kim HY.; Kang MJ.; Jung H.;Oh Y.; Kim D.; Koh J.; Cho S.; Jeon YK.; Lee EB.; Lee SH.; Shin E.; Kim HM.; Yi EC. & Chung DH. (2021).Soluble Fas ligand drives autoantibody-induced arthritis by binding to DR5/TRAIL-R2. eLife, 10:e48840.https://doi.org/10.7554/eLife.48840
Krishnan A.; Fei F.; Jones A.; Busto P.; Marshak-Rothstein A.; Ksander BR. & Gregory-Ksander M. (2016). Overexpression of Soluble Fas Ligand following Adeno-Associated Virus Gene Therapy Prevents Retinal Ganglion Cell Death in Chronic and Acute Murine Models of Glaucoma. The Journal of Immunology, 197 (12) 4626-4638. DOI: 10.4049/jimmunol.1601488
Yamada A.; Arakaki R.; Saito M.; Kudo Y. & Ishimaru N. (2017). Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance. Frontiers in Immunology, 8:403. 8doi: 10.3389/fimmu.2017.00403
Nada HR. (2016). Fas receptor. Global Dermatology, 3: DOI: 10.15761/GOD.1000167.
Holler N.; Tardivel A.; Kovacsovics-Bankowski M.; Hertig S.; Gaide O.; Martinon F.; Tinel A.; Deperthes D.; Calderara S.; Schulthess T.; Engel J.; Schneider P. & Tschopp J. (2003). Two Adjacent Trimeric Fas Ligands Are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex. Molecular and Cellular Biology, 23(4):1428_1440. Doi: 10.1128/MCB.23.4.1428-1440.2003
SAS. (2012) . Statistical Analysis System, User's Guide. Statistical. Version 9.1th ed. SAS. Inst. Inc. Cary. N.C. USA.
Tanaka M.; Suda T.; Haze K.; Nakamura N.; Sato K.; Kimura F.; Motoyoshi K.; Mizuki M.; Tagawa S.; Ohga S.; Hatake K.; Drummond AH. & Nagata S. (1996). Fas ligand in human serum. Nature Medicine, 2(3): 317–322.
De Maria R.; Testa U.; Luchetti L.; Zeuner A.; Stassi G.; Pelosi E.; Riccioni R.; Felli N.; Samoggia P. &Peschle C. (1999). Apoptotic Role of Fas/Fas Ligand System in the Regulation of Erythropoiesis. Blood, 93(3): 796-803.
Shimizu M.; Kondo M.; Ito Y.; Kume H.; Suzuki R. &Yamaki K. (2005). Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. Cancer Detect Prev., 29(2):175-180.
Bellone G.; Smirne C.; Carbone A.; Mareschi K.; Dughera L.; Farina EC.; Alabiso O.; Valente G.; Emanuelli G. & Rodeck U. (2000). Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. Clinical Cancer Research,6(6):2448-2455.
O’Connell J.; O’Sullivan GC.; Collins JK. & Shanahan F. (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. The Journal of experimental medicine, 184(3):1075–1082.
Gratas C.; Tohma Y.; Barnas C.; Taniere P.; Hainaut P. & Ohgaki H. (1998). Upregulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Research, 58(10): 2057–2062.
Kozlowski M.; Kowalczuk O.; Sulewska A.; Dziegielewski P.; Lapuc G.; Laudanski W.; Niklinska W.; Chyczewski L.; Niklinski J. & Laudanski J. (2007). Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus. Folia Histochemica et Cytobiologica, 45(3):199-204.
Lim S. (2002). Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas. Oncology Reports, 9(1): 103-107.
Kanda Y.; Chiba S.; Tanaka Y.; Kami M.; Saito M.;Izutsu K.;Asai T.; Yuji K.; Ogawa S.; Honda H.;Mitani K.;Usuki K.; Urabe A.; Shirakawa K.; Yatomi T.; Nakamura N.; Yazaki Y. & Hirai H. (1999). Increased Serum Soluble Fas Ligand Associated with Recurrent B-Cell Non-Hodgkin's Lymphoma after Autologous Peripheral Blood Stem Cell Transplantation. Leukemia & Lymphoma, 34(5-6): 625-628. https://doi.org/10.3109/10428199909058494
Urbaniak-Kujda D.; Jaźwiec B.; Tomaszewska-Toporska B.; Wołowiec D.; Kapelko-Słowik K. & Kuliczkowski K. (2002). Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemia. Polskie Archiwum Medycyny Wewnetrznej, 108(3): 873-878.
Murakami M.; Sasaki T.; Miyata H.; Yamasaki S; KuwaharaK. & Chayama K. (2004). Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma. Oncology Reports, 11(6): 1183-1186.
Jiang S.; Moriarty-Craige SE.; Li C.; Lynn MJ.; Cai J.; Jones DP. & Sternberg P. (2008). Associations of plasma-soluble fas ligand with aging and age-related macular degeneration. Investigative Ophthalmology & Visual Science, 49(4): 1345-1349.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Sahar Radhi Yasir
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
